CoMentis is a biotech company focused on the research and development of small molecule drugs to treat neurovascular diseases such as Alzheimer's disease (AD), age-related macular degeneration (AMD) and other cognitive disorders. Originally founded in 2004 as Athenagen, Inc., the company was re-named CoMentis following its August 2006 merger with Zapaq, Inc., which created a leading neurovascular disease franchise.

Publications 6 show all

  • 1
    Alcohol Drinking/metabolism
  • 1
    Alcohol Drinking/pathology
  • 1
    Alzheimer Disease/metabolism
  • 1
    Amyloid Precursor Protein Secretases/antagonists & inhibitors
  • 1
    Amyloid Precursor Protein Secretases/genetics
  • 1
    Amyloid beta-Peptides/metabolism
  • 1
    Aquaporin 4/metabolism
  • 1
    Aspartic Acid Endopeptidases/genetics
  • 1
    Brain Edema/metabolism
  • 1
    Brain Edema/pathology

Patents 188show all

  • 90
    A61B - Diagnosis
  • 64
    C07D - Heterocyclic compounds
  • 29
    A61N - Electrotherapy
  • 29
    G16H - Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data
  • 26
    G06F - Electric digital data processing
  • 15
    A61K - Preparations for medical, dental, or toilet purposes
  • 15
    C07C - Acyclic or carbocyclic compounds
  • 10
    G06Q - Data processing systems or methods, specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes
  • 6
    C07B - General methods of organic chemistry
  • 6
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium

Clinical Trials 18show all

4Phase 23Phase 1/Phase 22N/A2Phase 1

SEC Filings show all


Contact Information

280 Utah Avenue, Suite 275
South San Francisco, CA 94080
United States


Total FundingEmployeesLast Funding DateStatus

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2006-06-11$21,000,000Series A
2006-09-28$50,000,000Series BSanderling Ventures, Clarus VenturesCharter Life Sciences, Index Ventures, Astellas Venture Management
2016-03-19$4,500,000Series E
2007-12-03$12,000,000Series CWellington Partners
2008-06-05$20,000,000Series DCharter Life Sciences, Clarus Ventures, Astellas Pharma, Robin J. Cook, Claris Lifesciences, John Donovan, John P. Cooke, Muralitharan Kengatharan, Sanderling Ventures, Index Ventures, Scott Harkonen, John Higgins

SEC Form D Funding Events

2008-05-16Unknown Unknown Other (Paper Filing)